Rokit Healthcare, an artificial intelligence-based hyper-personalized organ regeneration platform company, announced on the 24th that it has secured a foothold in the European public healthcare market by beginning supply of its "AI Skin Organ Regeneration Platform" to a public hospital in Milan, Italy.
This supply was made through Italy's national health service system, the SSN (Servizio Sanitario Nazionale), and is expected to become a key reference for future expansion into the European public insurance market.
Italy has one of the highest burdens of diabetic foot complications in Europe. The country's adult diabetes prevalence rate is approximately 10%, with 4.47 million patients, and lifetime incidence reaches up to 34%. Annual demand for diabetic foot regeneration continues to grow due to aging populations and increasing rates of comorbid vascular diseases.
The Italian medical community has long pointed out the amputation risks and structural limitations of conventional dressing-centered treatments. Rokit Healthcare emphasized that its AI hyper-personalized customized organ regeneration technology is overcoming these limitations and emerging as a core platform for diabetic foot treatment.
This achievement is particularly significant as it represents "securing access to Italian public hospital channels." The result is interpreted as Rokit Healthcare's platform gaining recognition for both clinical improvement effects and medical cost reduction capabilities within Italy's healthcare system, where public hospitals hold considerable influence.
A Rokit Healthcare official said, "Administrative data research in Italy reports diabetic foot as a high-burden disease with medical costs reaching up to 16,702 euros. Through our platform, we aim to reduce amputation rates and shorten hospitalization periods. We are targeting a 90% diabetic foot regeneration rate while lowering cost burdens for high-risk patients."
Industry observers view this Milan public hospital entry as going beyond simple supply to serve as a practical testbed for expansion across Europe based on CE MDR approval. Using Italy, which has high acceptance of regenerative medicine, as a base, Rokit Healthcare plans to rapidly target not only Southern European markets including Spain and Portugal but also Eastern European markets such as Poland and the Czech Republic.
A Rokit Healthcare official explained, "Entry into Italian public hospitals is an important starting point for applying AI organ regeneration platforms to European public healthcare. Based on the clinical data we secure, we plan to accelerate our strategy to capture the approximately 2.4 trillion won European diabetic foot regeneration market."